On June 8, at the site of the Single Distributor, the chairman of the company, Erkhat Iskaliyev, met with the Egyptian International Pharmaceutical Industrial Company - EIPICO (Egyptian International Pharmaceutical Industries Company), as well as with the Kazakh Invest national company.
The Egyptian pharmaceutical company is considering the possibility of creating production in Kazakhstan with potential export to nearby countries.
The head of the Single Distributor, after welcoming the participants and foreign guests, expressed gratitude for the increased interest of the Egyptian side in cooperation with Kazakhstan in the field of pharmaceutical production.
After his opening speech, Ahmad Kilani, Chairman of the Board of Directors and Managing Director of the Egyptian International Pharmaceutical Company EIPICO, made a presentation on the activities of the enterprise.
EIPICO is an Egyptian pharmaceutical manufacturer. The company produces 276 medicines in 25 therapeutic groups. It is the leader of the Egyptian export of the pharmaceutical industry (21% of the total export of pharmaceutical products in Egypt).
Having studied the pharmaceutical market in Kazakhstan, EIPICO expressed interest in expanding its production and creating joint production sites for the production of pharmaceutical products in the territory of the Republic of Kazakhstan with potential export to neighboring countries.
In the coming years, the Egyptian company intends to focus on increasing registered drugs in Kazakhstan, cooperation in the field of pharmaceuticals and science, as well as covering export markets.
Thus, during the meeting, the parties discussed the possibility of building a plant for the production of medicines in Kazakhstan, and also considered potential sites and further steps for the implementation of the initiative.
Currently, EIPICO exports its products to about 70 countries, 33 of them are African countries. Cooperation with Egypt will become a “gateway to Africa” for Kazakhstan, allowing it to rely on the promotion of Kazakhstani products to the markets of the African continent and the implementation of joint investment projects.
Partnership with major world manufacturers is one of the important directions of the state strategy. The head of the Single Distributor spoke about the investment opportunities of Kazakhstan, the benefits of joint cooperation and the prospects for further partnership between the two countries.
In addition, the guests were told about the single distribution system, contract manufacturing mechanisms and work with a number of BigPharma companies on projects for the production of innovative drugs with the possibility of exporting to near and far abroad.
The Chairman of the Single Distributor also focused on the pharmaceutical industry of Kazakhstan and domestic pharmaceutical brands. The Kazakh pharmaceutical industry, thanks to effective government support measures, has a huge potential for profitable investments. According to available statistics, in recent years the industry has shown a positive trend in all key indicators.
Speaking about investments, the guests were presented with a guide for potential investors - INVESTMENT GUIDE BOOK, developed jointly with Kazakh Invest, which, on the principle of "one window", provides a platform for entry into the country of large drug brands from packaging to the full production cycle.
The meeting participants exchanged experience on the development of the pharmaceutical industry and the potential of investment partnerships. EIPICO, in turn, noted its full readiness in partnership with Kazakhstan and in achieving common goals.
The single distributor, for its part, is open and ready for cooperation and assistance in coordinating on issues arising in the process to improve and develop the pharmaceutical sector of the country and the healthcare sector as a whole.
Reference:
EIPICO was founded in the city of the Tenth Day of Ramadan in 1980 and began production in 1985 as a leading company in Egypt, the Middle East and North Africa for the production of pharmaceutical products. There is also 1 factory in Saudi Arabia.
EIPICO has 2 factories built on an area of 120,000 m2, which are fully operated in accordance with c GMP regulations to guarantee the safety and efficacy of their pharmaceutical products. In 2023, a third plant was opened in Egypt and 1 plant in Saudi Arabia.
EIPICO has the first biotechnology and genetic engineering research center in Egypt. The company produces more than 400 types of medicines, of which 65 are produced under licenses. The main drug of the company is interferon. EIPICO is the largest generic drug manufacturer in Egypt. The company manufactures 276 generic products across 25 therapeutic groups, valued at $170 million annually.
Source: Press Service of SK-Pharmacy LLP
